Dr. Laura Esserman is recognized for her groundbreaking work in personalized medicine, including the I-SPY TRIALs and RECAST trials. Her research has led to the development of new treatments and improved patient outcomes, and she is a vocal advocate for patients and the oncology community.
The AIM-HI Accelerator Fund has selected two companies, ResNovas Therapeutics and Chiara Biosciences, as winners of the 2025 Venture Competition. Both companies have demonstrated innovative approaches to targeted protein degradation and drug discovery, with potential to transform cancer treatment.
A portfolio start-up company of the AIM-HI Accelerator Fund, ILCT is developing engineered therapeutic interleukins for cancer treatment. The grant will support collaboration with Virginia Commonwealth University towards development of its commercialization efforts.